Accueil   Diary - News   All news Focus on Fluoptics

Focus on Fluoptics

Fluoptics, Lyonbiopole member’s, based in Grenoble, develops and markets innovative solutions in the field of fluorescence image-guided surgery. Early June, the company has obtained the Food and Drug Administration clearance for its clinical imaging system, Fluobeam®. In the meantime, Flupotics established a subsidiary in the United States, Fluoptics Imaging Inc. dedicated to the marketing of its innovative solutions.



The innovative solutions developed by Fluoptics combine optical imaging system in the near infrared and the use of injectable fluorescent tracers . They used to assist the surgeon in the operating room to help him see during the operation he can not discern with the naked eye . These solutions have many applications in the field of cancer surgery (removal of cancerous tumors , detection of the sentinel nodes ) but also cardiovascular surgery (Verification of blood flow ) , in reconstructive surgery ( vascularization verification shreds ) and in liver surgery (removal of tumors and metastases) .  



In early June, the company received certification from the Food and Drug Administration (FDA) for marketing in the US of its optical imaging system Fluobeam® . Read the Press Release At the same time , Fluoptics established a subsidiary in the United States , Fluoptics Imaging Inc. dedicated to the commercial distribution of innovative solutions .    


Odile Allard , CEO
Tel .: +33 (0) 4 38 78 28 78





By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree